about
Laparoscopic sleeve gastrectomy: More than a restrictive bariatric surgery procedure?Statins for primary cardiovascular prevention in the elderlyEfficacy of treatment for hyperglycemic crisis in elderly diabetic patients in a day hospital.Subclinical cardiovascular disease in type 2 diabetes mellitus: To screen or not to screen.Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational studyCarcinoid tumor of the thymus associated with Cushing's syndrome and dysgeusia: case report and review of the literature.Type 1 diabetes, metabolic syndrome and cardiovascular risk.Obesity and type 1 diabetes mellitus management.Bariatric surgery: to whom and when?Laparoscopic roux-en-y gastric bypass vs. laparoscopic sleeve gastrectomy for morbid obesity: a systematic review and meta-analysis of lipid effects at one year post-surgery.Role of First-Trimester HbA1c as a Predictor of Adverse Obstetric Outcomes in a Multiethnic Cohort.Predictors of Hypertension Remission and Recurrence After Bariatric Surgery.[Cardiovascular prevention in diabetes mellitus: A multifactorial challenge].[Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors].Sleeve gastrectomy and Roux-en-Y gastric bypass are equally effective in correcting insulin resistance.Role of A1c in the postpartum screening of women with gestational diabetes.Gestational diabetes in a multiethnic population of Spain: clinical characteristics and perinatal outcomes.[Bariatric surgery for the treatment of type 2 diabetes mellitus].Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes.[Atherogenic dyslipidemia in patients with type 1 diabetes mellitus].Preoperative predictors of weight loss at 4 years following bariatric surgery.Is first-trimester HbA1c useful in the diagnosis of gestational diabetes?Past, present and future of pharmacotherapy for obesity.Laparoscopic gastric bypass versus laparoscopic sleeve gastrectomy as a definitive surgical procedure for morbid obesity. Mid-term results.Neurotensin and Nonalcoholic Fatty Liver Disease: Beyond Obesity.Clinical Value of Thyrotropin Receptor Antibodies for the Differential Diagnosis of Interferon Induced Thyroiditis.Can bariatric surgery improve cardiovascular risk factors in the metabolically healthy but morbidly obese patient?Impact of different criteria on type 2 diabetes remission rate after bariatric surgery.Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial.Can Helicobacter pylori Eradication Treatment Modify the Metabolic Response to Bariatric Surgery?[Bone mass loss after sleeve gastrectomy: a prospective comparative study with gastric bypass].[Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].Estimated Glucose Disposal Rate in Assessment of the Metabolic Syndrome and Microvascular Complications in Patients with Type 1 Diabetes.Impact of overt diabetes diagnosed in pregnancy in a multi-ethnic cohort in SpainGestational diabetes mellitus in a multiethnic population in Spain: Incidence of and factors associated to impaired glucose tolerance one year after deliveryBiochemical behaviour of an incidentally diagnosed silent corticotroph adenomaBariatric surgery and hypertension: implications and perspectives after the GATEWAY randomized trialMid-term results of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy compared-results of the SLEEVEPASS and SM-BOSS trials.[Quality of food intake after bariatric surgery: vertical gastrectomy versus gastric bypass][Descriptive study on the improvement of quality perceived after the introduction of a clinical pathway by patients subjected to bariatric surgery]
P50
Q26778002-DC946463-690E-44D4-9A7A-12597A0E605EQ26783401-97D5B698-2048-46C0-820B-3B1CF5A2CB99Q33636971-3D67CFFD-9575-4B5D-9E21-336CFDB6524EQ34179368-D7AC1E92-8C19-4AD7-9BC6-691E40BA9605Q35073928-3038D6BF-645A-4E83-B551-BD898CF6D684Q37622127-E85A5F32-BD9C-4B89-B606-1379740A54AEQ38166074-8DE2B1F0-209F-4CC2-9C15-BD874632DDFBQ38270105-FDE60475-604B-40A5-A051-D8D848C35686Q38349391-333E9761-9AE7-4791-844B-B2A5BD347F97Q39138430-BC0773BD-E540-495D-B560-CA2CEC4DCB37Q39158736-2EC93903-14AA-49E2-B025-D2426350378FQ40561823-648B640F-DC51-479E-8591-9A438702239AQ41060990-CE6C7873-89F6-4EB6-89C7-13CBFFDCCBAAQ43119834-15F2E37C-990D-46BF-B3AA-97663A84F79DQ44360948-136AF77F-ABF1-4BB9-9566-8DF256FA1C7CQ44682380-D567E0FB-3538-49C9-A732-2E5D363E3761Q44761878-B3A3D3C7-F901-4C1E-BCC1-DE27C03630FFQ44788178-DE19697C-F6DE-4B0F-857E-77E0CE9A28FFQ45936679-7CD8575D-2D9C-437F-8234-B6C9AE434C39Q46482161-F48B2BD9-CB5A-48F5-86FE-532DBE478A08Q47409163-F398AC5D-133B-43D0-9BAD-DC9AC4A7BC6BQ47684580-B5D6EADC-DF42-4B48-9115-4ABE07B1343EQ47936360-43642279-73D3-4DC4-9384-63B2EBB6AB69Q48209081-D8E1850C-4CD5-436D-8B19-6D9A86486E7AQ50109012-F715AB63-9461-49E3-89AF-8BCB49019F00Q50276074-DED0DCDC-6BDD-4909-9033-45D8815A1D17Q50459084-E02B34E4-1588-4332-8761-4B9148287B52Q51322343-6242F21F-CCD3-46F8-9C06-242FC1AB8E06Q51359915-72159823-A27C-49FF-9A74-06008E0EC685Q51744999-096BDDCD-A2E8-4FDD-8856-CAC22666280BQ54106517-09191C3B-6600-4C3E-996A-AE1C81F743C4Q54523463-2B7BB51E-216C-43C1-B17A-EAF640F65176Q54912237-1FE81A49-1E2A-4226-84F8-E2A37EB457FAQ57453282-AA7628F3-BD2B-41A6-A3F3-629704151039Q57481550-7B27ADA4-7ACB-42DA-9DC9-25A8AE044B86Q57644298-C3A984B0-9F2E-4E3E-892B-4F0D4B4E46A8Q64262531-14CC0817-B4F8-45A2-A5E3-176882B7657DQ64896789-E61B8A1F-5A58-409B-A169-9AB4792EC768Q83129625-3A9AAF71-21FB-4C15-81AF-F10C9A20F41CQ83564854-71131022-AC1D-44C4-ADDB-081302ACDFA0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Benaiges
@ast
David Benaiges
@en
David Benaiges
@es
David Benaiges
@nl
David Benaiges
@sl
type
label
David Benaiges
@ast
David Benaiges
@en
David Benaiges
@es
David Benaiges
@nl
David Benaiges
@sl
prefLabel
David Benaiges
@ast
David Benaiges
@en
David Benaiges
@es
David Benaiges
@nl
David Benaiges
@sl
P106
P21
P31
P496
0000-0001-5411-364X